NovoCure Reports Q1 2026 Earnings, Highlights Optune PAX Launch and Financial Performance
NovoCure reported Q1 2026 net revenue of $174 million, up 12% YoY, and raised full-year revenue guidance to $690–$710 million. The company also launched Optune PAX in the U.S. for pancreatic cancer, with early commercial success and positive clinical trial results. Despite a net loss of $71 million, the company remains optimistic about future catalysts and profitability.
Topics: Clinical Trials Earnings FDA Approval Revenue Growth Stock Performance